Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients.
Montiel V, Lobysheva I, Gérard L, Vermeersch M, Perez-Morga D, Castelein T, Mesland JB, Hantson P, Collienne C, Gruson D, van Dievoet MA, Persu A, Beauloye C, Dechamps M, Belkhir L, Robert A, Derive M, Laterre PF, Danser AHJ, Wittebole X, Balligand JL. Montiel V, et al. Among authors: derive m. EBioMedicine. 2022 Mar;77:103893. doi: 10.1016/j.ebiom.2022.103893. Epub 2022 Feb 23. EBioMedicine. 2022. PMID: 35219085 Free PMC article.
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
François B, Wittebole X, Ferrer R, Mira JP, Dugernier T, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Pickkers P, Vandenhende F, Garaud JJ, Sánchez M, Salcedo-Magguilli M, Laterre PF. François B, et al. Among authors: derive m. Intensive Care Med. 2020 Jul;46(7):1425-1437. doi: 10.1007/s00134-020-06109-z. Epub 2020 May 28. Intensive Care Med. 2020. PMID: 32468087 Clinical Trial.
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.
Francois B, Lambden S, Gibot S, Derive M, Olivier A, Cuvier V, Witte S, Grouin JM, Garaud JJ, Salcedo-Magguilli M, Levy M, Laterre PF. Francois B, et al. Among authors: derive m. BMJ Open. 2021 Jul 7;11(7):e042921. doi: 10.1136/bmjopen-2020-042921. BMJ Open. 2021. PMID: 34233965 Free PMC article.
sTREM-1 is a specific biomarker of TREM-1 pathway activation.
Jolly L, Carrasco K, Salcedo-Magguilli M, Garaud JJ, Lambden S, van der Poll T, Mebazaa A, Laterre PF, Gibot S, Boufenzer A, Derive M. Jolly L, et al. Among authors: derive m. Cell Mol Immunol. 2021 Aug;18(8):2054-2056. doi: 10.1038/s41423-021-00733-5. Epub 2021 Jul 19. Cell Mol Immunol. 2021. PMID: 34282296 Free PMC article. No abstract available.
Inflammation-Induced Coagulopathy Substantially Differs Between COVID-19 and Septic Shock: A Prospective Observational Study.
Dechamps M, De Poortere J, Martin M, Gatto L, Daumerie A, Bouzin C, Octave M, Ginion A, Robaux V, Pirotton L, Bodart J, Gerard L, Montiel V, Campion A, Gruson D, Van Dievoet MA, Douxfils J, Haguet H, Morimont L, Derive M, Jolly L, Bertrand L, Dumoutier L, Castanares-Zapatero D, Laterre PF, Horman S, Beauloye C. Dechamps M, et al. Among authors: derive m. Front Med (Lausanne). 2022 Jan 17;8:780750. doi: 10.3389/fmed.2021.780750. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35111777 Free PMC article.
Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill.
Dechamps M, De Poortere J, Octave M, Ginion A, Robaux V, Pirotton L, Bodart J, Gruson D, Van Dievoet MA, Douxfils J, Haguet H, Morimont L, Derive M, Jolly L, Bertrand L, Laterre PF, Horman S, Beauloye C. Dechamps M, et al. Among authors: derive m. Int J Mol Sci. 2023 Apr 14;24(8):7278. doi: 10.3390/ijms24087278. Int J Mol Sci. 2023. PMID: 37108440 Free PMC article.
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
François B, Lambden S, Garaud JJ, Derive M, Grouin JM, Asfar P, Darreau C, Mira JP, Quenot JP, Lemarié J, Mercier E, Lacherade JC, Vinsonneau C, Fivez T, Helms J, Badie J, Levy M, Cuvier V, Salcedo-Magguilli M, Laszlo-Pouvreau AL, Laterre PF, Gibot S; ESSENTIAL investigators. François B, et al. Among authors: derive m. EClinicalMedicine. 2023 Jun;60:102013. doi: 10.1016/j.eclinm.2023.102013. Epub 2023 May 31. EClinicalMedicine. 2023. PMID: 37350989 Free PMC article.
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
François B, Lambden S, Fivez T, Gibot S, Derive M, Grouin JM, Salcedo-Magguilli M, Lemarié J, De Schryver N, Jalkanen V, Hicheur T, Garaud JJ, Cuvier V, Ferrer R, Bestle M, Pettilä V, Mira JP, Bouisse C, Mercier E, Vermassen J, Huberlant V, Vinatier I, Anguel N, Levy M, Laterre PF; ASTONISH investigators. François B, et al. Among authors: derive m. Lancet Respir Med. 2023 Oct;11(10):894-904. doi: 10.1016/S2213-2600(23)00158-3. Epub 2023 May 31. Lancet Respir Med. 2023. PMID: 37269870 Clinical Trial.
Persistently Elevated Soluble Triggering Receptor Expressed on Myeloid Cells 1 and Decreased Monocyte Human Leucocyte Antigen DR Expression Are Associated With Nosocomial Infections in Septic Shock Patients.
Venet M, Bidar F, Derive M, Delwarde B, Monard C, Hengy B, Jolly L, Rimmelé T, Lukaszewicz AC, Monneret G, Venet F. Venet M, et al. Among authors: derive m. Crit Care Explor. 2023 Feb 24;5(3):e0869. doi: 10.1097/CCE.0000000000000869. eCollection 2023 Mar. Crit Care Explor. 2023. PMID: 36861044 Free PMC article.
39 results